Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

Cited by (1,018)

Items 101–200 of 1,018

1. Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G 1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2
   Jennifer L. Spratlin, Roger B. Cohen, Matthew Eadens, Lia Gore, D. Ross Camidge, Sami Diab, Stephen Leong, Cindy L. O’Bryant, Laura Q.M. Chow, Natalie Julie Serkova et al. · 2010 · Journal of Clinical Oncology
2. IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC
   Mark A. Socinski, Makoto Nishio, Robert M. Jotte, Federico Cappuzzo, Francesco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez‐Abreu, Denis Moro‐Sibilot, Christian A. Thomas et al. · 2021 · Journal of Thoracic Oncology
3. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor‐2 tyrosine kinase with potent activity in vitro and in vivo
   Shu Tian, Haitian Quan, Chengying Xie, Haiyi Guo, Fangfang Lü, Yongping Xu, Jin Li, Liguang Lou · 2011 · Cancer Science
4. Targeting the microenvironment in solid tumors
   Carmen Belli, Dario Trapani, Giulia Viale, Paolo D’Amico, Bruno Achutti Duso, Paolo Della Vigna, Franco Orsi, Giuseppe Curigliano · 2018 · Cancer Treatment Reviews
5. Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
   Gettinger, Scott, Rizvi, Naiyer A., Chow, Laura Q., Borghaei, Hossein, Brahmer, Julie, Ready, Neal, Gerber, David E., Shepherd, Frances A., Antonia, Scott, Goldman, Jonathan W. et al. · 2016 · Journal of Clinical Oncology
6. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors
   Andrew R. Reynolds, Ian R. Hart, Alan R Watson, Jonathan C. Welti, Rita G Silva, Stephen David Robinson, Georges Da Violante, Morgane Gourlaouen, Mishal Salih, Matt Jones et al. · 2009 · Nature Medicine
7. Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy
   Sonia A. Patel, Monique B. Nilsson, Xiuning Le, Tina Cascone, Rakesh K. Jain, John Victor Heymach · 2022 · Clinical Cancer Research
8. New and emerging targeted treatments in advanced non-small-cell lung cancer
   Fred R. Hirsch, Kenichi Suda, Jacinta Wiens, Paul A. Bunn · 2016 · The Lancet
9. The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets
   Steven L. Wood, Maria Pernemalm, Philip A.J. Crosbie, Anthony David Whetton · 2013 · Cancer Treatment Reviews
10. A review on the effects of current chemotherapy drugs and natural agents in treating non–small cell lung cancer
    Chih‐Yang Huang, Da‐Tong Ju, Chih-Fen Chang, P. Muralidhar Reddy, Bharath Kumar Velmurugan · 2017 · Biomedicine
11. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
    Zhou, Caicun, Chen, Gongyan, Huang, Yunchao, Zhou, Jianying, Lin, LiZhu, Feng, Jifeng, Wang, Zhehai, Shu, Yongqian, Shi, Jianhua, Hu, Yi et al. · 2021 · The Lancet Respiratory Medicine
12. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial
    N. Thatcher, Fred R. Hirsch, Alexander Valerievich Luft, Aleksandra Szczęsna, Tudor–Eliade Ciuleanu, Mircea Dediu, Rodryg Ramlau, Rinat Galiulin, Beatrix Bálint, György Losonczy et al. · 2015 · The Lancet Oncology
13. Angiogenesis Inhibitors: Current Strategies and Future Prospects
    Kristina M. Cook, William Douglas Figg · 2010 · CA A Cancer Journal for Clinicians
14. Lung cancer: New biological insights and recent therapeutic advances
    Suresh S. Ramalingam, Taofeek Kunle Owonikoko, Fadlo Raja Khuri · 2011 · CA A Cancer Journal for Clinicians
15. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
    Zhou, C., Wu, Y.L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S. et al. · 2015 · Annals of Oncology
16. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant Disease
    Ohashi, Kadoaki, Maruvka, Yosef E., Michor, Franziska, Pao, William · 2013 · Journal of Clinical Oncology
17. NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 5.2018
    David S. Ettinger, Dara L. Aisner, Douglas E. Wood, Wallace Akerley, Jessica Ruth Bauman, Joe Yujiao Chang, Lucian R. Chirieac, Thomas Anthony D’Amico, Thomas J. Dilling, M.C. Dobelbower et al. · 2018 · Journal of the National Comprehensive Cancer Network
18. Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics
    Priti S. Hegde, Jeffrey J. Wallin, Christoph Mancao · 2017 · Seminars in Cancer Biology
19. Tumor Microvasculature and Microenvironment: Novel Insights Through Intravital Imaging in Pre-Clinical Models
    Dai Fukumura, Dan Gabriel Duda, Lance L. Munn, RAKESH K. JAIN · 2010 · Microcirculation
20. Vascular Endothelial Growth Factor as an Anti-Angiogenic Target for Cancer Therapy
    Gang Niu, Xiaoyuan Shawn Chen · 2010 · Current Drug Targets
21. Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099
    Lynch, Thomas J., Patel, Taral, Dreisbach, Luke, McCleod, Michael, Heim, William J., Hermann, Robert C., Paschold, Eugene, Iannotti, Nicholas O., Dakhil, Shaker, Gorton, Steven et al. · 2010 · Journal of Clinical Oncology
22. Vessel co-option in cancer
    Elizabeth A. Kuczynski, Peter B. Vermeulen, Francesco Pezzella, Robert S. Kerbel, Andrew R. Reynolds · 2019 · Nature Reviews Clinical Oncology
23. Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non–Small-Cell Lung Cancer
    Giorgio V. Scagliotti, Silvia Novello, Joachim von Pawel, Martin Reck, José Rodrigues Pereira, Michael Thomas, José Elias Miziara, Beatrix Bálint, Filippo de Marinis, Alan M. Keller et al. · 2010 · Journal of Clinical Oncology
24. Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
    Naiyer A. Rizvi, Matthew David Hellmann, Julie Renee Brahmer, Rosalyn Anne Juergens, Hossein Borghaei, Scott N. Gettinger, Laura Q.M. Chow, David E. Gerber, Scott Andrew Laurie, Jonathan Wade Goldman et al. · 2016 · Journal of Clinical Oncology
25. O2⋅− and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate
    Schoenfeld, Joshua D., Sibenaller, Zita A., Mapuskar, Kranti A., Wagner, Brett A., Cramer-Morales, Kimberly L., Furqan, Muhammad, Sandhu, Sonia, Carlisle, Thomas L., Smith, Mark C., Abu Hejleh, Taher et al. · 2017 · Cancer Cell
26. Rapid Chemotherapy-Induced Acute Endothelial Progenitor Cell Mobilization: Implications for Antiangiogenic Drugs as Chemosensitizing Agents
    Yuval Shaked, Erik Henke, Jeanine M.L. Roodhart, Patrizia Mancuso, Marlies H.G. Langenberg, Marco Angelo Colleoni, Laura G.M. Daenen, Shan Man, Ping Xu, Urban Emmenegger et al. · 2008 · Cancer Cell
27. The Role of VEGF and EGFR Inhibition: Implications for Combining Anti–VEGF and Anti–EGFR Agents
    Josep M. Tabernero · 2007 · Molecular Cancer Research
28. Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor Pathway
    Nguyen, Kim-Son H., Kobayashi, Susumu, Costa, Daniel B. · 2009 · Clinical Lung Cancer
29. Immunotherapy of cancer in 2012
    John M. Kirkwood, Lisa Helene Butterfield, Ahmad A. Tarhini, Hassane M. Zarour, Paweł Kaliński, Soldano Ferrone · 2012 · CA A Cancer Journal for Clinicians
30. Pneumonitis in Non–Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors
    Karthik S. Suresh, Khinh Ranh Voong, Bairavi Shankar, Patrick M. Forde, David S. Ettinger, Kristen Ashley Marrone, Ronan Joseph Kelly, Christine L. Hann, Benjamin Philip Levy, Josephine Louella Feliciano et al. · 2018 · Journal of Thoracic Oncology
31. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis
    Sanjaykumar Hapani, David T. W. Chu, Shenhong Wu · 2009 · The Lancet Oncology
32. Treatment-Related Mortality With Bevacizumab in Cancer Patients
    Vishal Navnitray Ranpura, Sanjaykumar Hapani, Shenhong Wu · 2011 · JAMA
33. Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib
    Vince D. Cataldo, Don Lynn Gibbons, Roman Perez-Soler, Alfonso Quintás‐Cardama · 2011 · New England Journal of Medicine
34. Cell-Based Therapeutics: The Next Pillar of Medicine
    Michael Andrew Fischbach, Jeffrey A. Bluestone, Wendell A. Lim · 2013 · Science Translational Medicine
35. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial
    Roy S. Herbst, Yan Ping Sun, Wilfried Eberhardt, Paul R. Germonpré, Nagahiro Saijo, Caicun Zhou, Jie Wang, Longyun Li, Fairooz F. Kabbinavar, Yukito Ichinose et al. · 2010 · The Lancet Oncology
36. Diagnostic Assay Based on hsa-miR-205 Expression Distinguishes Squamous From Nonsquamous Non–Small-Cell Lung Carcinoma
    Danit Lebanony, Hila Benjamin, Shlomit Gilad, Meital Ezagouri, Avital Dov, Karin Ashkenazi, Nir Gefen, Shai Izraeli, Gideon Rechavi, Harvey Ira Pass et al. · 2009 · Journal of Clinical Oncology
37. Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma
    Daitaro Yoshikawa, Hidenori Ojima, M Iwasaki, Nobuyoshi Hiraoka, T Kosuge, S Kasai, S Hirohashi, Tatsuhiro Shibata · 2007 · British Journal of Cancer
38. Classification and Pathology of Lung Cancer
    Min Zheng · 2016 · Surgical Oncology Clinics of North America
39. Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1–Selected Advanced Non–Small-Cell Lung Cancer (BIRCH)
    Solange Peters, Scott N. Gettinger, Melissa Lynne Johnson, Pasi Antero Janne, Marina Chiara Garassino, Daniel Christian Christoph, Chee‐Keong Toh, Naiyer A. Rizvi, Jamie E. Chaft, Enric Carcereny et al. · 2017 · Journal of Clinical Oncology
40. CXCL12 (SDF1α)-CXCR4/CXCR7 Pathway Inhibition: An Emerging Sensitizer for Anticancer Therapies?
    Dan Gabriel Duda, Sergey V. Kozin, Nathaniel D. Kirkpatrick, Lei Xu, Dai Fukumura, Rakesh K. Jain · 2011 · Clinical Cancer Research
41. Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration
    Alexander Edward Dela Cruz Drilon, Jeffrey William Clark, Jared M. Weiss, Sai‐Hong Ignatius Ou, D. Ross Camidge, Benjamin Solomon, Gregory A. Otterson, Liza Cosca Villaruz, Gregory J. Riely, Rebecca Suk Heist et al. · 2020 · Nature Medicine
42. Phase II Study of Efficacy and Safety of Bevacizumab in Combination With Chemotherapy or Erlotinib Compared With Chemotherapy Alone for Treatment of Recurrent or Refractory Non–Small-Cell Lung Cancer
    Roy S. Herbst, Vincent O’Neill, Louis Fehrenbacher, Chandra Prakash Belani, Philip Bonomi, Lowell L. Hart, O.O. Melnyk, David Albert Ramies, Ming Lin, Alan B. Sandler · 2007 · Journal of Clinical Oncology
43. Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review
    Syed Hasan Raza Jafri, Runhua Shi, Glenn Morris Mills · 2013 · BMC Cancer
44. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial
    Roy S. Herbst, Rafat Ansari, Frederique Bustin, Patrick J. Flynn, Lowell L. Hart, Gregory A. Otterson, Gordana Vlahovic, Chang-Heok Soh, Paula G. O’Connor, John Daniel Hainsworth · 2011 · The Lancet
45. Anticancer drug resistance: An update and perspective
    Ruth Nussinov, Chung‐Jung Tsai, Hyunbum Jang · 2021 · Drug Resistance Updates
46. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas
    Mark Agulnik, Jessica Lee Yarber, Scott H. Okuno, Margaret von Mehren, Borko D. Jovanovic, Bruce Brockstein, Andrew M. Evens, Robert S. Benjamin · 2012 · Annals of Oncology
47. Taxanes in cancer treatment: Activity, chemoresistance and its overcoming
    Luciana Mosca, Andrea Ilari, Francesco Fazi, Yehuda G. Assaraf, Gianni Colotti · 2021 · Drug Resistance Updates
48. Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer
    Karthik S. Suresh, Jarushka Naidoo, Cheng Ting Lin, Sonye Karen Danoff · 2018 · CHEST Journal
49. Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung Cancer
    Lecia Van Dam Sequist, Joachim von Pawel, Edward Graeme Garmey, Wallace Akerley, Wolfram Brugger, Dora Ferrari, Yinpu Chen, Daniel Botelho Costa, David E. Gerber, С. В. Орлов et al. · 2011 · Journal of Clinical Oncology
50. Jekyll and Hyde: the role of the microenvironment on the progression of cancer
    Michael D. Allen, J. Louise Jones · 2010 · The Journal of Pathology
51. BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non–Small-Cell Lung Cancer
    Caicun Zhou, Yi-Long Lung Cancer Wu, Gongyan Chen, Xiaoqing Liu, Yunzhong Zhu, Shun Lü, Jifeng Feng, Jianxing He, Baohui Han, Jie Wang et al. · 2015 · Journal of Clinical Oncology
52. Combination of antiangiogenesis with chemotherapy for more effective cancer treatment
    Jie Ma, David J. Waxman · 2008 · Molecular Cancer Therapeutics
53. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice
    Sequist, L.V., Heist, R.S., Shaw, A.T., Fidias, P., Rosovsky, R., Temel, J.S., Lennes, I.T., Digumarthy, S., Waltman, B.A., Bast, E. et al. · 2011 · Annals of Oncology
54. Safety and Efficacy of Bevacizumab With Hypofractionated Stereotactic Irradiation for Recurrent Malignant Gliomas
    Philip H. Gutin, FABIO MASSAITI IWAMOTO, Kathryn P. Beal, Nimish A. Mohile, Sasan Karimi, Bob L. Hou, Stella C. Lymberis, Yoshiya Josh Yamada, Jenghwa Chang, Lauren E. Abrey · 2009 · International Journal of Radiation Oncology*Biology*Physics
55. PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer
    Jyoti D. Patel, Mark A. Socinski, Edward B. Garon, Craig H. Reynolds, David Robert Spigel, Mark R. Olsen, Robert C. Hermann, Robert M. Jotte, Thaddeus Beck, Donald Richards et al. · 2013 · Journal of Clinical Oncology
56. Cisplatin resistance: Preclinical findings and clinical implications
    Beate Köberle, Maja T. Tomicic, Svetlana Usanova, Bernd Kaina · 2010 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
57. Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial
    Nancy Y. Lee, Qiang Zhang, David G. Pfister, John Kim, Adam S. Garden, James Mechalakos, Kenneth Shung Hu, Quynh‐Thu Le, Alexander Dimitrios Colevas, Bonnie S. Glisson et al. · 2011 · The Lancet Oncology
58. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules
    Axel Grothey, Evanthia Galanis · 2009 · Nature Reviews Clinical Oncology
59. Five-Year Survival in EGFR -Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs
    Jessica J. Lin, Stephanie Cardarella, Christine Lydon, Suzanne Eleanor Dahlberg, David Michael Jackman, Pasi Antero Janne, Bruce Evan Johnson · 2015 · Journal of Thoracic Oncology
60. Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease.
    Goel, S., Wong, A. H.-K., Jain, R. K. · 2012 · Cold Spring Harbor Perspectives in Medicine
61. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question
    Fojo, T., Grady, C. · 2009 · JNCI Journal of the National Cancer Institute
62. Non-small cell lung cancer (NSCLC): A review of risk factors, diagnosis, and treatment
    Yaser Alduais, Haijun Zhang, Fan Fan, Jing Chen, Baoan Chen · 2023 · Medicine
63. Non–Small Cell Lung Cancer
    David S. Ettinger, Wallace Akerley, Hossein Borghaei, Andrew C. Chang, Richard T. Cheney, Lucian R. Chirieac, Thomas Anthony D’Amico, Todd L. Demmy, Apar Kishor Ganti, Ramaswamy Govindan et al. · 2012 · Journal of the National Comprehensive Cancer Network
64. Anti-angiogenesis therapy in cancer: Current challenges and future perspectives
    Farbod Shojaei · 2012 · Cancer Letters
65. A pathway-based classification of human breast cancer
    Michael L. Gatza, Joseph E. Lucas, William Thomas Barry, Jong Wook Kim, Quanli Wang, Matthew D. Crawford, Michael Datto, Michael J. Kelley, Bernard Mathey-Prévôt, Anil Potti et al. · 2010 · Proceedings of the National Academy of Sciences
66. Outcomes for Elderly, Advanced-Stage Non–Small-Cell Lung Cancer Patients Treated With Bevacizumab in Combination With Carboplatin and Paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599
    Suresh S. Ramalingam, Suzanne Eleanor Dahlberg, Corey Jay Langer, Robert J. Gray, Chandra Prakash Belani, Julie Renee Brahmer, Alan B. Sandler, Joan H. Schiller, David H. Johnson · 2007 · Journal of Clinical Oncology
67. Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance
    George N. Naumov, Monique B. Nilsson, Tina Cascone, Alexandra Briggs, Oddbjørn Straume, Lars A. Akslen, Eugene Lifshits, Lauren A. Byers, Li Xu, Hua-Kang Wu et al. · 2009 · Clinical Cancer Research
68. Squamous Cell Carcinoma of the Lung: Molecular Subtypes and Therapeutic Opportunities
    Pablo Perez-Moreno, Elisabeth M. Brambilla, Roman Kurt Thomas, Jean‐Charles Soria · 2012 · Clinical Cancer Research
69. Association of Depression and Anxiety on Quality of Life, Treatment Adherence, and Prognosis in Patients with Advanced Non-small Cell Lung Cancer
    Oscar G. Arrieta, Laura Angulo, Carolina Núñez-Valencia, Yuzmiren Dorantes-Gallareta, Eleazar Omar Macedo, Dulce María Martínez-López, Salvador Alvarado, José Francisco Corona-Cruz, Luis Fernando Oñate-Ocaña · 2012 · Annals of Surgical Oncology
70. Management of hypertension in angiogenesis inhibitor-treated patients
    Hassane Izzedine, Stéphane Éderhy, François Goldwasser, Jean‐Charles Soria, Gerard Alain Milano, Ariel A. Cohen, David Khayat, Jean‐Philippe Spano · 2009 · Annals of Oncology
71. Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC
    Xiuning Le, Monique B. Nilsson, Jonathan Wade Goldman, Martin Reck, Kazuhiko Nakagawa, T. Kato, Luis Paz Ares, Bente Frimodt‐Moller, Katharina Wolff, Carla Visseren‐Grul et al. · 2020 · Journal of Thoracic Oncology
72. A framework for the development of effective anti-metastatic agents
    Robin L. Anderson, Theo Balasas, Juliana Callaghan, R. Charles Coombes, JEFF EVANS, Jacqueline A. Hall, Sally A. Kinrade, David Jones, Paul S. Jones, Robert J. Jones et al. · 2018 · Nature Reviews Clinical Oncology
73. Nintedanib: From Discovery to the Clinic
    Gerald J. Roth, Rudolf Binder, Florian Colbatzky, Claudia Dallinger, Rozsa Schlenker‐Herceg, Frank Hilberg, Stefan Lutz Wollin, Rolf Kaiser · 2014 · Journal of Medicinal Chemistry
74. Local Therapy with Continued EGFR Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in EGFR-Mutant Advanced Lung Cancers That Have Developed Acquired Resistance to EGFR Tyrosine Kinase Inhibitors
    Helena Alexandra Yu, Camelia S. Sima, James Guoxian Huang, Stephen Barnett Solomon, Andreas Rimner, Paul K. Paik, Maria Catherine Pietanza, Christopher G. Azzoli, Naiyer A. Rizvi, Lee M. Krug et al. · 2013 · Journal of Thoracic Oncology
75. Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: Implications for scheduling of anti-angiogenic drugs
    Van der Veldt, Astrid A.M., Lubberink, Mark, Bahce, Idris, Walraven, Maudy, de Boer, Michiel P., Greuter, Henri N.J.M., Hendrikse, N. Harry, Eriksson, Jonas, Windhorst, Albert D., Postmus, Pieter E. et al. · 2012 · Cancer Cell
76. Systemic Immune-inflammation Index, Based on Platelet Counts and Neutrophil-Lymphocyte Ratio, Is Useful for Predicting Prognosis in Small Cell Lung Cancer
    Hong, Xuan, Cui, Baohong, Wang, Meng, Yang, Zhaoyang, Wang, Li, Xu, Qingyong · 2015 · The Tohoku Journal of Experimental Medicine
77. The potential of the mevalonate pathway for enhanced isoprenoid production
    Pan Liao, Andréa Hemmerlin, Thomas J. Bach, Mee‐Len Chye · 2016 · Biotechnology Advances
78. Systemic Chemotherapy for Advanced Non-Small Cell Lung Cancer: Recent Advances and Future Directions
    Suresh S. Ramalingam, Chandra Prakash Belani · 2008 · The Oncologist
79. VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management
    Hassane Izzedine, Christophe Massard, Jean‐Philippe Spano, François Goldwasser, David Khayat, Jean‐Charles Soria · 2009 · European Journal of Cancer
80. Markers of Response for the Antiangiogenic Agent Bevacizumab
    Diether Lambrechts, Heinz‐Josef Lenz, Sanne de Haas, Peter Carmeliet, Stefan J. Scherer · 2013 · Journal of Clinical Oncology
81. Biomarkers for immune checkpoint inhibition in non–small cell lung cancer (NSCLC)
    Joseph Nicholas Bodor, Yanis Boumber, Hossein Borghaei · 2019 · Cancer
82. Combination Targeted Therapy With Sorafenib and Bevacizumab Results in Enhanced Toxicity and Antitumor Activity
    Nilofer Saba Azad, Edwin M. Posadas, Virginia E. Kwitkowski, Seth M. Steinberg, Lokesh Jain, Christina M. Annunziata, Lori M. Minasian, Gisele Sarosy, Herbert L. Kotz, Ahalya Premkumar et al. · 2008 · Journal of Clinical Oncology
83. Sex Differences in Cancer: Epidemiology, Genetics and Therapy
    Kim, Hae-In, Lim, Hyesol, Moon, Aree · 2018 · Biomolecules & Therapeutics
84. VEGF-A: a critical regulator of blood vessel growth
    Napoleone Ferrara · 2009 · European Cytokine Network
85. Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non–Small-Cell Lung Cancer: AVAPERL (MO22089)
    Barlesi, Fabrice, Scherpereel, Arnaud, Rittmeyer, Achim, Pazzola, Antonio, Ferrer Tur, Neus, Kim, Joo-Hang, Ahn, Myung-Ju, Aerts, Joachim G.J.V., Gorbunova, Vera, Vikström, Anders et al. · 2013 · Journal of Clinical Oncology
86. MiR-126 restoration down-regulate VEGF and inhibit the growth of lung cancer cell lines in vitro and in vivo
    Bo Liu, Xiaochun Peng, Xiaoli Zheng, Jun Wang, Yongwen Qin · 2009 · Lung Cancer
87. Control of the Immune Response by Pro-Angiogenic Factors
    Thibault Voron, Elie Marcheteau, Simon Pernot, Orianne Colussi, Éric Tartour, Julien Taı̈eb, Magali Terme · 2014 · Frontiers in Oncology
88. Review: Side Effects of Approved Molecular Targeted Therapies in Solid Cancers
    Christian Widakowich, Gilberto de Castro, Evandro de Azambuja, Phuong Dinh, Ahmad Hussein Awada · 2007 · The Oncologist
89. Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non–Small-Cell Lung Cancer
    Mark A. Socinski, Silvia Novello, Julie Renee Brahmer, Rafael Rosell, José Miguel Sánchez, Chandra Prakash Belani, Ramaswamy Govindan, James N. Atkins, Heidi H. Gillenwater, Cinta Pallarés et al. · 2008 · Journal of Clinical Oncology
90. Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non–Small-Cell Lung Cancer
    Primo N. Lara, Jean‐Yves Douillard, Kazuhiko Nakagawa, Joachim von Pawel, Mark James McKeage, Istvan Albert, György Losonczy, Martin Reck, Dae Seog Heo, Xiaolin Fan et al. · 2011 · Journal of Clinical Oncology
91. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial
    Rowan T. Chlebowski, Ann G. Schwartz, Heather A. Wakelee, Garnet L. Anderson, Marcia L. Stefanick, JoAnn E. Manson, Rebecca J. Rodabough, Jason W. Chien, Jean Wactawski‐Wende, Margery L S Gass et al. · 2009 · The Lancet
92. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    G. D’Addario, Martin Früh, Martin Reck, Pia Baumann, Walter Klepetko, Enriqueta Felip · 2010 · Annals of Oncology
93. Targeting angiogenesis in oncology, ophthalmology and beyond
    Yihai Cao, Róbert Langer, Napoleone Ferrara · 2023 · Nature Reviews Drug Discovery
94. EML4-ALK: Honing In on a New Target in Non–Small-Cell Lung Cancer
    Leora Horn, William J. Pao · 2009 · Journal of Clinical Oncology
95. Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer
    Soria, J.-C., Mauguen, A., Reck, M., Sandler, A.B., Saijo, N., Johnson, D.H., Burcoveanu, D., Fukuoka, M., Besse, B., Pignon, J.-P. · 2013 · Annals of Oncology
96. Modulation of murine breast tumor vascularity, hypoxia and chemotherapeutic response by exercise
    Betof, Allison S., Lascola, Christopher D., Weitzel, Douglas, Landon, Chelsea, Scarbrough, Peter M., Devi, Gayathri R., Palmer, Gregory, Jones, Lee W., Dewhirst, Mark W. · 2015 · JNCI: Journal of the National Cancer Institute
97. Pathways mediating VEGF-independent tumor angiogenesis
    Napoleone Ferrara · 2009 · Cytokine & Growth Factor Reviews
98. In Vivo VEGF Imaging with Radiolabeled Bevacizumab in a Human Ovarian Tumor Xenograft
    Wouter Bastiaan Nagengast, Elisabeth G.E. de Vries, Geke A.P. Hospers, Nanno H. Mulder, Johan R. de Jong, Harry Hollema, Adrienne H. Brouwers, Guus A.M.S. van Dongen, Lars R. Perk, Marjolijn N. Lub–de Hooge · 2007 · Journal of Nuclear Medicine
99. IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain
    Naoyuki Nogami, Fabrice Barlési, Mark A. Socinski, Martin Reck, Christian A. Thomas, Federico Cappuzzo, Tony S.K. Mok, Gene Grant Finley, Joachim G.J.V. Aerts, Francesco Orlandi et al. · 2021 · Journal of Thoracic Oncology
100. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study
     Andrew Xiuxuan Zhu, Jeffrey A. Meyerhardt, Lawrence Scott Blaszkowsky, Avinash R. Kambadakone, Alona Muzikansky, Hui Zheng, Jeffrey William Clark, Thomas Adam Abrams, Jennifer Ai-wen Chan, Peter C. Enzinger et al. · 2009 · The Lancet Oncology